Drug profile

The FDA adverse-event record for Tulathromycin Inj Sol

49 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Tulathromycin Inj Sol. See the species affected, top reactions, and outcomes below.

49
adverse-event reports
75.5%
death-coded share
Cattle
most-reported species
34
Death - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
49
Total Reports
37
Deaths Reported
75.5%
Death Rate

Active Ingredients

Tulathromycin Inj Sol

Administration Routes

SubcutaneousUnknownIntramuscularTopicalParenteral

Species Affected

Cattle 44
Unknown 2
Human 2
Pig 1

Most Affected Breeds

Cattle (other) 29
Unknown 4
Aberdeen Angus 4
Crossbred Bovine/Cattle 3
Mixed (Cattle) 3
Cattle (unspecified) 2
Holstein-Friesian also known as Holstein 2
Pig (unknown) 1
Simmental 1

Most Reported Reactions

Death 34
Lack of efficacy - NOS 31
Necropsy performed 4
Lack of efficacy (mycoplasma) - NOS 3
Lack of efficacy (bacteria) - Histophilus somni 3
Recumbency 3
Anaphylaxis 3
Fibrinous (broncho) pneumonia/fibrinous pleuropneumonia 2
Hypersensitivity reaction 2
Death by euthanasia 2
Laboured breathing 2
Physical label missing 1

Outcome Breakdown

Died
36 (44.4%)
Ongoing
22 (27.2%)
Outcome Unknown
16 (19.8%)
Recovered/Normal
5 (6.2%)
Euthanized
2 (2.5%)

Tulathromycin Inj Sol Adverse Event Insights

49 reports name Tulathromycin Inj Sol; 37 recorded a death outcome (75.5% of reported events, not a population-level mortality rate). Active ingredient: Tulathromycin Inj Sol. Administration routes: Subcutaneous, Unknown, Intramuscular, Topical.

By species: Cattle (44 reports), Unknown (2 reports), Human (2 reports). By breed: Cattle (other) (29), Unknown (4), Aberdeen Angus (4).

Leading clinical signs: Death (34), Lack of efficacy - NOS (31), Necropsy performed (4), Lack of efficacy (mycoplasma) - NOS (3). Outcome, 81 coded reports: Died leads at 44.4%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.